The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Regulatory News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.60
Bid: 1.50
Ask: 1.70
Change: -0.10 (-5.88%)
Spread: 0.20 (13.333%)
Open: 1.65
High: 1.65
Low: 1.60
Prev. Close: 1.70
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IMAGING BIOMETRICS UPGRADES IB CLINIC™ SOFTWARE

26 Nov 2020 07:00

RNS Number : 5438G
IQ-AI Limited
26 November 2020
 

26 November 2020

IQ-AI Ltd

("IQ-AI" or the "Company")

IMAGING BIOMETRICS UPGRADES IB CLINIC™ SOFTWARE

 

IQ-AI today announces that its subsidiary, Imaging Biometrics®, LLC (IB), has made available release 20.11 of its IB Clinic™ software platform. The new release incorporates multiple new enhancement requests received from clients, as well as workflow efficiencies engineered by IB's developers. Ultimately, this release underscores IB's commitment to quality and helping clinicians improve care for their patients.

 

IB Clinic consists of perfusion weighted imaging and permeability computation modules IB Neuro and IB DCE, diffusion weighted imaging analysis module IB Diffusion, image co-registration and manipulation module IB Delta Suite, and IB Rad Tech, which streamlines and automates customizable workflows. While the products contained in IB Clinic continue to be available as plugins to the Mac-based medical imaging viewers, aycan workstation and OsiriX MD, they are also now available as platform-independent automated applications for both in-house and cloud-based processing. Both options generate consistent quantitative output regardless of where or when a patient is scanned, a feature unique to IB Clinic.

 

"This latest release further builds upon our proven track record of delivering scientifically proven advancements to clinicians," said Michael Schmainda, CEO of IB.

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

 

-ENDS-

For further information, please contact:

IQ-AI Limited

Trevor Brown/Vinod Kaushal/Qu Li

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

ABOUT Imaging Biometrics, LLC

Imaging Biometrics®, a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PFUBABLTMTMTBIM
Date   Source Headline
23rd Oct 20089:35 amRNSEPT Disclosure
21st Oct 20082:11 pmRNSInterim Management Statement
17th Oct 20089:24 amRNSEPT Disclosure
14th Oct 200811:36 amRNSEPT Disclosure
14th Oct 20089:31 amRNSEPT Disclosure
10th Oct 20089:44 amRNSEPT Disclosure
9th Oct 20089:26 amRNSEPT Disclosure
8th Oct 20088:53 amRNSEPT Disclosure
6th Oct 200810:48 amRNSEPT Disclosure
3rd Oct 20089:14 amBUSRule 8.3 - Flying Brands
1st Oct 20088:31 amRNSEPT Disclosure
30th Sep 20089:00 amRNSBlocklisting Interim Review
25th Sep 20088:42 amRNSEPT Disclosure
24th Sep 200810:47 amRNSEPT Disclosure
16th Sep 20088:32 amRNSEPT Disclosure
15th Sep 20089:21 amRNSEPT Disclosure
12th Sep 20089:49 amRNSEPT Disclosure - Replacement
12th Sep 20089:10 amRNSEPT Disclosure - Correction
12th Sep 20088:53 amRNSEPT Disclosure
11th Sep 20085:40 pmBUSRule 8.3 - Flying Brands
3rd Sep 20088:35 amRNSEPT Disclosure
2nd Sep 20088:54 amRNSEPT Disclosure
28th Aug 200810:07 amRNSEPT Disclosure
27th Aug 20083:17 pmBUSRule 8.3 - Flying Brands
27th Aug 20089:28 amRNSEPT Disclosure
26th Aug 200811:04 amRNSEPT Disclosure
26th Aug 20089:53 amRNSEPT Disclosure
22nd Aug 20089:16 amRNSEPT Disclosure
22nd Aug 20088:31 amRNSEPT Disclosure
21st Aug 20088:42 amRNSEPT Disclosure
20th Aug 20089:02 amRNSEPT Disclosure
19th Aug 20089:11 amRNSEPT Disclosure
18th Aug 200810:42 amRNSEPT Disclosure
18th Aug 20089:52 amRNSEPT Disclosure
14th Aug 20089:25 amRNSEPT Disclosure
13th Aug 20082:53 pmPRNRule 8.3 - Flying Brands
13th Aug 200810:17 amBUSRule 8.3 - Flying Brands
13th Aug 20089:06 amRNSEPT Disclosure
12th Aug 20089:22 amBUSRule 8.3 - Flying Brands
12th Aug 20088:34 amRNSEPT Disclosure
12th Aug 20088:23 amRNSEPT Disclosure
11th Aug 20081:24 pmPRNRule 8.3 - Flying Brands Limited
11th Aug 200811:00 amRNSEPT Disclosure
11th Aug 200810:23 amBUSRule 8.3 - Flying Brands
11th Aug 20088:58 amRNSEPT Disclosure
8th Aug 200810:17 amRNSEPT Disclosure
8th Aug 20089:48 amRNSEPT Disclosure
7th Aug 20083:42 pmRNSStatement re Possible Offer
1st Aug 20087:00 amRNSInterim Results
3rd Jul 20086:23 pmRNSTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.